Anika Therapeutics Inc (NASDAQ:ANIK) Sellers Rose Their Shorts By 2.92% As Of May 16, 2018

May 16, 2018 - By Samuel McNeil

Anika Therapeutics, Inc. (NASDAQ:ANIK) Corporate Logo

Big Money Sentiment decreased to 1.37 in 2017 Q4. It has change of 0.05, from 2017Q3’s 1.42. The ratio is negative due to Anika Therapeutics, Inc. positioning: 12 sold and 45 reduced. 24 funds took holdings and 54 increased holdings. Investors holded 12.29 million in 2017Q3 but now own 12.26 million shares or 0.18% less.
Oaktop Cap Mngmt Ii Lp accumulated 12,500 shs. Advisors Asset Mngmt Inc accumulated 0.01% or 7,894 shs. Tower Limited Liability Company (Trc), a New York-based fund reported 220 shs. Healthinvest Prtnrs has invested 13.04% of its capital in Anika Therapeutics, Inc. (NASDAQ:ANIK). Portolan Cap Management Lc invested in 14,556 shs. Thompson Davis And Incorporated invested 0.05% of its capital in Anika Therapeutics, Inc. (NASDAQ:ANIK). Hutchin Hill Cap Limited Partnership accumulated 12,400 shs. Smith Asset Mgmt Lp owns 1,490 shs or 0% of their US capital. Blair William And Il holds 0% or 6,020 shs. State Of Alaska Department Of Revenue holds 0% or 2,902 shs. Moreover, Gotham Asset Management has 0.03% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK). Earnest Partners Ltd Limited Liability Company, Georgia-based fund reported 1,500 shs. Aqr Management Ltd Liability Corp stated it has 42,824 shs. Parametric Portfolio Assocs Ltd Liability Company, Washington-based fund reported 11,651 shs. The Missouri-based Stifel Fincl has invested 0.03% in Anika Therapeutics, Inc. (NASDAQ:ANIK).

Change of 2.92% for Anika Therapeutics Inc (NASDAQ:ANIK)’s shorted shares was noted. FINRA announced shorted shares of ANIK’s total 1.20M shares. The 1.17M previous shares are up with 2.92%. With Average volume 140,800, ANIK’s former position will take 9 days to recover. Anika Therapeutics Inc float short is 8.36%.

ANIK is hitting $40.09 during the last trading session, after increased 5.09%.Anika Therapeutics, Inc. has 470,688 shares volume, 252.83% up from normal. ANIK is uptrending and has moved 15.35% since May 16, 2017. ANIK outperformed the S&P500 by 3.80%.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally.The firm is valued at $591.14 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology.The P/E ratio is 19. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

In total 3 analysts cover Anika Therapeutics Inc (NASDAQ:ANIK). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:ANIK)’s analyst reports since December 28, 2017 according to StockzIntelligence Inc. On Friday, May 4 the stock of Anika Therapeutics, Inc. (NASDAQ:ANIK) has “Outperform” rating given by Barrington Research. On Wednesday, January 24 First Analysis upgraded the shares of ANIK in report to “Overweight” rating. On Friday, February 23 the company was downgraded by Barrington Research.

For more Anika Therapeutics, Inc. (NASDAQ:ANIK) news brought out recently go to:,,, or The titles are as follows: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” brought out on April 29, 2018, “Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest …” on May 01, 2018, “J&J cost cutting plan may pressure suppliers – Bloomberg” with a publish date: April 17, 2018, “Mid-Afternoon Market Update: Dow Turns Positive; Anika Therapeutics Shares Fall Following Disappointing Q1 Results” and the last “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” with publication date: May 04, 2018.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.